全文获取类型
收费全文 | 987篇 |
免费 | 185篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 25篇 |
妇产科学 | 8篇 |
基础医学 | 11篇 |
口腔科学 | 7篇 |
临床医学 | 49篇 |
内科学 | 47篇 |
皮肤病学 | 3篇 |
神经病学 | 9篇 |
特种医学 | 14篇 |
外国民族医学 | 4篇 |
外科学 | 31篇 |
综合类 | 43篇 |
预防医学 | 4篇 |
眼科学 | 368篇 |
药学 | 134篇 |
中国医学 | 3篇 |
肿瘤学 | 426篇 |
出版年
2023年 | 18篇 |
2022年 | 16篇 |
2021年 | 49篇 |
2020年 | 40篇 |
2019年 | 39篇 |
2018年 | 50篇 |
2017年 | 52篇 |
2016年 | 66篇 |
2015年 | 92篇 |
2014年 | 117篇 |
2013年 | 256篇 |
2012年 | 80篇 |
2011年 | 77篇 |
2010年 | 88篇 |
2009年 | 69篇 |
2008年 | 53篇 |
2007年 | 23篇 |
2006年 | 7篇 |
2005年 | 5篇 |
2004年 | 2篇 |
2003年 | 1篇 |
2002年 | 1篇 |
排序方式: 共有1201条查询结果,搜索用时 140 毫秒
101.
Shigeru YAMAGUCHI Hiroaki MOTEGI Yukitomo ISHI Michinari OKAMOTO Ryosuke SAWAYA Hiroyuki KOBAYASHI Shunsuke TERASAKA Kiyohiro HOUKIN 《Neurologia medico-chirurgica》2021,61(4):245
Bevacizumab (BEV) is a key anti-angiogenic agent used in the treatment for recurrent glioblastoma multiforme (GBM). The aim of this study was to investigate whether cytoreductive surgery prior to treatment with BEV contributes to prolongation of survival for patients with recurrent GBM. We retrospectively analyzed the treatment outcomes of 124 patients with recurrent GBM who were initially treated with the Stupp protocol between 2006 and 2019. Given that BEV has only been available in Japan since 2013, we grouped the patients into two groups according to the time of first recurrence: the pre-BEV group (N = 51) included patients who had recurrence before BEV approval, and the BEV group (N = 73) included patients with recurrence after BEV approval. The overall survival after first recurrence (OS-R) was analyzed according to the treatment strategy. Among 124 patients, 27 patients (19.4%) received cytoreductive surgery. There were nine cases in the pre-BEV group and 18 cases in the BEV group. Although the mean extent of resection for both groups was almost equal, OS-R was significantly different. The median OS-R was 8.1 m in the pre-BEV group and 16.3 m in the BEV group (P = 0.007). Multivariate analysis revealed that the unavailability of BEV postoperatively (P = 0.03) and decreasing performance status by surgery (P = 0.01) were significant poor prognostic factors for survival after surgery. With the advent of BEV, cytoreductive surgery might provide superior survival benefit at the time of GBM recurrence, especially in cases where surgery can be performed without deteriorating the patient’s condition. 相似文献
102.
Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial 下载免费PDF全文
Kathryn M. Field Greg Fitt Mark A. Rosenthal John Simes Anna K. Nowak Elizabeth H. Barnes Kate Sawkins Christine Goh Bradford A. Moffat Simon Salinas Lawrence Cher Helen Wheeler Elizabeth J. Hovey Pramit M. Phal CABARET/COGNO Investigators 《Asia-Pacific Journal of Clinical Oncology》2018,14(5):e359-e365
103.
Bevacizumab‐enhanced antitumor effect of 5‐fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular endothelial growth factor receptor 2‐specificity protein 1 pathway 下载免费PDF全文
Wenyue Liu Jingwei Zhang Xuequan Yao Chao Jiang Ping Ni Lingge Cheng Jiali Liu Suiying Ni Qianying Chen Qingran Li Kai Zhou Guangji Wang Fang Zhou 《Cancer science》2018,109(10):3294-3304
Bevacizumab (Bv) can be used synergistically with fluoropyrimidine‐based chemotherapy to treat colorectal cancer. Whether and how it affects the delivery of fluoropyrimidine drugs is unknown. The present study aimed to explore the effect of Bv on the delivery of 5‐fluorouracil (5‐FU) to tumors and the underlying mechanism from metabolic perspective. Bv enhanced the anti‐tumor effects of 5‐FU in LoVo colon cancer xenograft mice and increased the 5‐FU concentration in tumors without affecting hepatic 5‐FU metabolism. Interestingly, Bv remarkably upregulated thymidine phosphorylase (TP) in tumors, which mediated the metabolic activation of 5‐FU. Although TP is reported to promote angiogenesis and resistance, the combination of Bv and 5‐FU resulted in anti‐angiogenesis and vessel normalization in tumors, indicating that the elevated TP mainly contributed to the enhanced response to 5‐FU. Bv also induced TP upregulation in LoVo cancer cells. Treatment with vascular endothelial growth factor receptor 2 (VEGFR2) antagonist apatinib and VEGFR2 silencing further confirmed TP upregulation. Bv and apatinib both enhanced the cytotoxicity of 5‐FU in LoVo cells, but there was no synergism with adriamycin and paclitaxel. We further demonstrated that the effect of Bv was dependent on VEGFR2 blockade and specificity protein 1 activation via MDM2 inhibition. In summary, Bv enhanced the accumulation of 5‐FU in tumors and the cytotoxicity of 5‐FU via TP upregulation. We provide data to better understand how Bv synergizes with 5‐FU from metabolic perspective, and it may give clues to the superiority of Bv in combination with fluoropyrimidine drugs compared to other chemotherapeutic drugs in colon cancer. 相似文献
104.
Multiparametric characterization of response to anti‐angiogenic therapy using USPIO contrast‐enhanced MRI in combination with dynamic contrast‐enhanced MRI 下载免费PDF全文
105.
Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E4203) 下载免费PDF全文
Neal J. Meropol MD Yang Feng MD MS MPH Jean L. Grem MD Mary F. Mulcahy MD Paul J. Catalano ScD John S. Kauh MD Michael J. Hall MD Joel N. Saltzman MD Thomas J. George MD Jr Jeffrey Zangmeister MD Elena G. Chiorean MD Puneet S. Cheema MD Peter J. O'Dwyer MD Al B. Benson MD III 《Cancer》2018,124(4):688-697
106.
Randomized phase 2 trial of pemetrexed,pemetrexed/bevacizumab,and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non–small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2 下载免费PDF全文
107.
Bevacizumab in combination with different platinum‐based doublets in the first‐line treatment for advanced nonsquamous non‐small‐cell lung cancer: A network meta‐analysis 下载免费PDF全文
Yaxiong Zhang Zhonghan Zhang Li Zhang 《International journal of cancer. Journal international du cancer》2018,142(8):1676-1688
Platinum‐based doublet chemotherapy with or without bevacizumab is the standard treatment for untreated advanced nonsquamous non‐small‐cell lung cancer (NS‐NSCLC). However, adding bevacizumab to chemotherapies other than paclitaxel–carboplatin is, though widely applied clinically, largely unjustified due to the lack of head‐to‐head data. We performed a Bayesian network meta‐analysis (NMA) to address this important issue. Data of 8,548 patients from 18 randomized controlled trials (RCTs) receiving six treatments, including taxane–platinum (Taxane–Pt), gemcitabine–platinum (Gem–Pt), pemetrexed–platinum (Pem–Pt), taxane–platinum + bevacizumab (Taxane–Pt + B), gemcitabine–platinum + bevacizumab (Gem–Pt + B) and pemetrexed–platinum + bevacizumab (Pem–Pt + B), were incorporated into the analyses. Direct and indirect evidence of overall survival (OS) and progression‐free survival (PFS) were synthesized at the hazard ratio (HR) scale and evidence of objective response rate (ORR) and serious adverse events (SAE) were synthesized at the odds ratio (OR) scale. Taxane–Pt + B showed significant advantages in OS (HR = 0.79, p < 0.001), PFS (HR = 0.54, p < 0.001) and ORR (OR = 2.7, p < 0.001) over Taxane–Pt with comparable tolerability (OR = 3.1, p = 0.08). Gem–Pt + B showed no OS benefit compared to any other treatment. No significant differences were detected between Pem–Pt + B and Pem–Pt in four outcomes. In terms of the benefit‐risk ratio, Pem–Pt and Taxane–Pt + B were ranked the first and second, respectively. In conclusion, in the first‐line treatment for advanced NS‐NSCLC, Taxane–Pt and Gem–Pt are the most and least preferable regimens to be used with bevacizumab, respectively. Adding bevacizumab to Pem–Pt remains unjustified because it fails to improve efficacy or tolerability. In terms of the benefit‐risk ratio, Pem–Pt and Taxane–Pt + B are the best and second‐best treatment for this population. 相似文献
108.
目的:系统评价未经化疗的新确诊或复发的EGFR突变晚期非小细胞肺癌患者使用厄洛替尼或联合贝伐珠单抗治疗的有效性和安全性。方法:检索PubMed及其他数据库中截至2020年10月24日所有相关的随机对照临床试验。结果:最终纳入3项符合条件的随机对照临床研究,共计464例患者。Meta分析结果显示,厄洛替尼联合贝伐珠单抗化疗显著延长了未经化疗的新确诊或复发EGFR突变晚期非小细胞肺癌患者的无进展生存期(P<0.000 1,HR=0.62,95% CI:0.49~0.78)。然而,联合化疗并没有明显改善该患者人群的客观缓解率(P=0.19,RR=1.08,95% CI:0.96~1.22)。联合化疗组中3级及以上级别的不良事件发生率明显高于对照组(P<0.000 01,RR=1.89,95% CI:1.62~2.19)。结论:厄洛替尼联合贝伐珠单抗治疗可能会显著延长未经化疗的新确诊或复发的EGFR突变晚期非小细胞肺癌患者群体的无进展生存期,但是无法显著提高客观缓解率。同时,联合治疗方式可能会增加3级及以上不良反应的发生。这些发现可能需要更多相关临床研究进行验证。 相似文献
109.
IntroductionNeoadjuvant chemotherapy (NAC) is the standard of care for locally advanced triple negative breast cancer, however, approximately 5% of cases show disease progression during NAC. Although downstaging is essential to create an opportunity for curative surgery and to improve the local control outcome in such a case, no additional line of chemotherapy has been established.Case presentationA 60-year-old woman was referred to our hospital for an axillary mass presenting three weeks ago and was diagnosed as having right locally advanced (T2N2M0, stage IIIA) triple negative breast cancer. After two courses of epirubicine and cyclophosphamide as NAC, disease progression was recognized and curative resection was considered impossible due to enlarged axillary lymph nodes showing invasion to surrounding tissue. As second-line chemotherapy, weekly paclitaxel with bevacizumab treatment was initiated and significant shrinkage was immediately obtained. A clinically complete response was diagnosed after four courses of weekly paclitaxel with bevacizumab and she underwent a right breast mastectomy with axillary lymph node dissection without major complications. Histopathological examination of surgical specimens showed no residual invasive or noninvasive disease and she was diagnosed as having a pathological complete response.ConclusionsAlthough the addition of bevacizumab to standard adjuvant chemotherapy is not recommended in unselected triple negative breast cancer, the potent effect on tumor shrinkage should be considered in the treatment of locally advanced triple negative breast cancer showing disease progression during standard NAC. 相似文献
110.